Intracellular Ca2+ regulating proteins in vascular smooth muscle cells are altered with type 1 diabetes due to the direct effects of hyperglycemia
© Searls et al; licensee BioMed Central Ltd. 2010
Received: 26 July 2009
Accepted: 1 February 2010
Published: 1 February 2010
Diminished calcium (Ca2+) transients in response to physiological agonists have been reported in vascular smooth muscle cells (VSMCs) from diabetic animals. However, the mechanism responsible was unclear.
VSMCs from autoimmune type 1 Diabetes Resistant Bio-Breeding (DR-BB) rats and streptozotocin-induced rats were examined for levels and distribution of inositol trisphosphate receptors (IP3R) and the SR Ca2+ pumps (SERCA 2 and 3). Generally, a decrease in IP3R levels and dramatic increase in ryanodine receptor (RyR) levels were noted in the aortic samples from diabetic animals. Redistribution of the specific IP3R subtypes was dependent on the rat model. SERCA 2 was redistributed to a peri-nuclear pattern that was more prominent in the DR-BB diabetic rat aorta than the STZ diabetic rat. The free intracellular Ca2+ in freshly dispersed VSMCs from control and diabetic animals was monitored using ratiometric Ca2+ sensitive fluorophores viewed by confocal microscopy. In control VSMCs, basal fluorescence levels were significantly higher in the nucleus relative to the cytoplasm, while in diabetic VSMCs they were essentially the same. Vasopressin induced a predictable increase in free intracellular Ca2+ in the VSMCs from control rats with a prolonged and significantly blunted response in the diabetic VSMCs. A slow rise in free intracellular Ca2+ in response to thapsigargin, a specific blocker of SERCA was seen in the control VSMCs but was significantly delayed and prolonged in cells from diabetic rats. To determine whether the changes were due to the direct effects of hyperglycemica, experiments were repeated using cultured rat aortic smooth muscle cells (A7r5) grown in hyperglycemic and control conditions. In general, they demonstrated the same changes in protein levels and distribution as well as the blunted Ca2+ responses to vasopressin and thapsigargin as noted in the cells from diabetic animals.
This work demonstrates that the previously-reported reduced Ca2+ signaling in VSMCs from diabetic animals is related to decreases and/or redistribution in the IP3R Ca2+ channels and SERCA proteins. These changes can be duplicated in culture with high glucose levels.
While improved care for people with diabetes has reduced the overall risk of complications and mortality, rates of mortality for people with diabetes is still two fold higher than those without diabetes [1, 2]. Cardiovascular disease accounts for a significant percentage of deaths of individuals inflicted with type 1 diabetes [3–7]. Even in young adults, cardiovascular events such as stroke are higher in people with type 1 diabetes than in those without diabetes . As the duration of life with diabetes increases, so increases the risk of cardiovascular events and mortality . Current management procedures focusing on tight glycemic control may have only marginal effects to halt the progression of large vessel disease .
While the majority of research effort concerning diabetic vascular disease has been focused on changes in the endothelial cells, alterations in the vascular smooth muscle cells (VSMCs) are also known to occur [11–13]. The VSMCs surrounding vessel walls, undergo increased proliferation, adhesion, and migration in conditions of hyperglycemia [14–17]. Several proteins and genes have been proposed as targets for hyperglycemic changes in the VSMCs including protein kinase C (PKC). Interestingly, many of them have a common upstream pathway that includes the release of calcium (Ca2+) from intracellular stores, including the sarcoplasmic reticulum (SR).
In VSMCs there are two channels that have been identified as important in the release of intracellular Ca2+ stores; the inositol 1,4,5-trisphosphate (IP3)-sensitive store and the ryanodine-sensitive store . In VSMCs, IP3 release of Ca2+ from intracellular stores is a common pathway for activation of many proteins including PKC  and PLC. Changes in basal levels of intracellular Ca2+ with diabetes are inconsistent, but Ca2+ transients in response to agonists such as angiotensin II are clearly attenuated in VSMCs from diabetic animals . The blunted IP3-induced Ca2+ responses could be due to changes in the intracellular Ca2+ channels, the intracellular Ca2+ storage site (SR), or the sarcoplasmic/endoplasmic Ca2+ ATPase (SERCA). This study examines changes in the intracellular Ca2+ regulatory proteins in two animal models of type 1 diabetes. The streptozotocin-induced diabetic rat is a well-established rat model using a toxin to destroy the pancreatic beta cells. The second model utilizes the DR-BB rat, which better mimics the autoimmune component of type 1 diabetes. Results from these animal models were compared to a cell culture model (A7r5) with hyperglycemia.
Materials and methods
Induction of Diabetes
Streptozotocin Rat Model
Seven week old male Sprague Dawley rats (Harlan, Indianapolis, IN) weighing 250-270 grams were injected intraperitoneally with 65 mg streptozotocin (STZ, Sigma, St. Louis, MO) per kg body weight (n = 15). Non-diabetic control rats (n = 12) were injected with vehicle (citrate buffer). Blood glucose levels greater than 250 mg/dL, measured by an Accu-Check Advantage glucometer (Boehringer Mannheim Corporation, Indianapolis, IN), indicated the development of diabetes.
Characteristics of Animal Models of Diabetes
STZ-Induced Diabetic Rat Model
DR-BB Diabetic Rat Model
453 ± 16
328 ± 14 *
217 ± 5
212 ± 19
Blood Glucose (mg/dL)
113 ± 5
554 ± 13 *
98 ± 2
295 ± 13 *
DR-BB Rat Model
Diabetes was induced in 21-26 day old Diabetes Resistant Bio-Breeding (DR-BB) Wistar rats using anti-RT6 monoclonal antibody (Dr. Dale Greiner, University of Mass) DS4.23 hybridoma in 2 ml of tissue culture medium injected 5 times/week in combination with polyinosinic-polycytidylic acid (Sigma), a non-specific immune system activator at 5 μl/g of body weight 3 times/week. Induction treatment was discontinued at the onset of diabetes as determined by a blood glucose level above 250 mg/dL. Diabetes typically occurred 2-3 weeks after the treatment was initiated. Within 1 week of diabetes development, the diabetic rats were treated with insulin (Humulin R, Humulin U and Humulin N; Eli Lilly, Indianapolis, IN) through subcutaneous implantation of an insulin-filled Alzet osmotic pump (Alza, model 2004, 0.25 μl/hr for 28 days; Mountain View, CA). Blood glucose was closely monitored for the remaining time, and hyperglycemic animals were given insulin injections as needed in amounts based upon the severity of hyperglycemia. Control rats underwent the same manipulations except pumps were filled with saline. Body weight and blood glucose were followed weekly, with the final values shown in Table 1. Diabetic animals (n = 7 female, 4 male) and their age matched controls (n = 6 female, 4 male) were euthanized after 8 weeks of diabetes.
Dissected aortas and femoral arteries were cleaned of adventitia in cold phosphate buffered saline (PBS) buffer. The vessels were cut lengthwise to expose the intima, which was gently swabbed to remove endothelial cells. Each vessel was pinned, lumen side up, in a small covered beaker containing Sylard Gel (Dow Corning, Midland, MI) and bathed in collagenase solution containing deoxyribonuclease I, collagenase type 2, soybean trypsin inhibitor (Worthington Biochemical Corporation, Lakewood, NJ) and bovine albumin (Sigma). After 30 minutes of shaking at 37°C, the first digest was discarded as it contained predominantly endothelial cells. New collagenase solution was added and further dispersions were gathered every 2 hours. Cells were gently centrifuged to remove the enzyme solution before being rinsed and re-suspended in media.
Cells from the A7r5 cell line (American Type Tissue Culture, Manassas, VA), derived from rat thoracic aorta, were grown in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, penicillin, and streptomycin at 37°C, 5% CO2. Cells were grown in flasks, then seeded in 100 mm dishes or on coverslips with glucose concentrations of either the supplier-recommended concentration (25 mM; referred to as medium) or high glucose (75 mM). Because 25 mM glucose is high compared to physiological serum levels, a third (low) glucose concentration was tested (5.5 mM). The effects of osmolarity were controlled by the addition of mannitol. Cells were grown to semi-confluence prior to testing.
Total proteins were extracted from tissue or cell culture using lysis buffer containing 10 mM Tris, pH 7.4, 1 mM sodium ortho-vanadate and 1% SDS. To separate nuclear and cytoplasmic proteins, the NE-PER kit (Pierce, Rockford, IL) was used. Each sample was concentrated by ultrafiltration using Microcon YM-10 (Millipore, Bedford, MA). Protein concentrations were measured in 96-well format using the BCA kit (Pierce, Rockford, IL) and a MRX microplate reader (Dynex Technologies, Chantilly, VA). A total of 30 or 50 μg of protein was loaded in each lane of 8, 10 or 4-15% gels. Rat cardiac tissue extract was used as a positive control for ryanodine receptor (RyR) and A-10 cell lysate (Santa Cruz, Santa Cruz, CA) was used for Inositol 1,4,5 trisphosphate receptors (IP3Rs). After electrophoretic separation, proteins were transferred from a gel to a PVDF membrane (Pierce) overnight. Ponceau's stain (Sigma) was used to assess protein loading prior to blotting. A standard immunoblotting protocol was performed. Primary antibodies to SERCA2, SERCA3, IP3R type I and RyR (Affinity BioReagents, Golden, CO), and IP3R type 2 and IP3R type 3 (Santa Cruz) were used. GAPDH was used as a housekeeping gene product (antibody, Santa Cruz). Anti-HSP90 (Santa Cruz) was used to assess the purity of the cytoplasmic extractions and anti-p62 (BD Transduction, Lexington, KY) or anti-USF-2 (Santa Cruz) were used to test the purity of the nuclear extracts. Detection was performed using enhanced chemiluminescent reagent (Pierce) or SuperSignal West Pico Chemiluminescent reagent (Pierce). Duplicates were made of each immunoblot experiment.
A7r5 cells were grown on cover slips in various glucose concentrations. Freshly dispersed VSMC were allowed to attach to glass coverslips for at least 2-4 hours in PBS at 37°C prior to fixation with 2% paraformaldehyde (Fisher Scientific, Palatine, IL). Fixed cells were rinsed with PBS, permeabilized with 1% Triton X-100 (Sigma) and rinsed well before blocking in 10% goat or donkey serum (Jackson Immunoresearch Laboratories, West Grove, PA). Cells were incubated with primary antibody (same as above) diluted in 5% non-fat dry milk (Bio-Rad, Helcules, CA) solution overnight in a cold box at manufacturer recommended concentrations. Alpha smooth muscle actin (Sigma) was used to identify SMC type. Cells were repeatedly rinsed in PBS before incubation with secondary antibody conjugated to Rhodamine Red or Cy 2 (Jackson ImmunoResearch) in a dark chamber. Brefeldin A (Invitrogen, Carlsbad, CA) was used to evaluate sarcoplasmic reticulum (SR). Coverslips were rinsed and allowed to air dry in the dark before mounting. Images were captured using an Olympus Fluoview 300 Confocal Microscope with the consistent confocal settings for each pair of control and diabetic cells per single primary antibody. Experiments were performed in triplicate.
Live Cell Intracellular Calcium Measurements
Freshly dispersed VSMCs or cultured A7r5 cells were allowed to attach to coverslips for 1 hour in PBS at 37°C before loading with 1 μM each of two Ca2+ sensitive fluorophores, Fluo-4/AM and Fura-Red/AM (invitrogen) by incubation at 37°C for 30-60 minutes. The coverslips were inserted into an Attofluor chamber (Molecular Probes) and rinsed with warm PBS. PBS with ethylene glycol tetraacetic acid (EGTA) to buffer extracellular Ca2+ (0 Ca2+), was added to the chamber mounted on the stage of a confocal microscope so that the measured Ca2+ changes were limited to the intracellular stores only. Baseline measurements were taken on quiescent cells for 3-4 minutes prior to the application of any agonist. Vasopressin (10 nM, Sigma) or thapsigargin (20 μM, Sigma) were added to the bath at the times indicated in the results section. Images were collected every 5 or 10 seconds using an inverted Nikon Eclipse TE 300/Bio-Rad MicroRadiance Plus Laser Scanning Confocal Microscope (Bio-Rad Laboratories, Germany) or an Olympus Fluoview 300 confocal microscope (Olympus, Center Valley, PA). Fluoview software was used to analyze Ca2+ signaling experiments. Time-to-peak was defined as the time of agonist application to the time the maximal magnitude of the response was obtained. The duration of the Ca2+ signal was defined as the time from the upstroke of the response to the return within 25% of initial baseline value.
All data points were normalized for background signal prior to statistical analysis. Fluoview software (Olympus, Melville, NY) was used to analyze Ca2+ signaling experiments. Adobe Photoshop (Adobe Systems, San Jose, CA) was used to analyze relative fluorescence intensity, and color analysis. Analysis of variance was performed for Ca2+ fluorescence and immunoblot density values using Sigma Stat software. When appropriate, statistical differences were assessed using Dunnett's test for multiple comparisons after a one-way analysis of variance using Sigma Stat (SPSS Inc, Chicago, IL). A probability level of p < 0.05 was defined as a significant difference.
Animal Models of Diabetes
The blood glucose levels were significantly higher (p < 0.001) in both diabetic rat models. However, the animals from the toxin-induced diabetes (STZ) were significantly more hyperglycemic when compared to the genetically-prone diabetic group (DR-BB) (Table 1, p < 0.001). This difference is due to the fact that uncontrolled diabetes is lethal in the DR-BB model and the animals were provided an insulin pump or injected with insulin daily after each became diabetic. In contrast, the STZ animals received no exogenous insulin. The body weight of control and diabetic DR-BB rats were comparable but in the STZ diabetic rat model, the diabetic rats demonstrated a significant decline in weight over time (Table 1, p < 0.001).
Diabetes Attenuated the Ca2+ responses in Freshly Dispersed SMCs
Delay in Agonist-Induced Ca2+ Transient in SMC from Diabetic Animals
Ca2+ Response (Time to Peak in seconds)
STZ-Induced Diabetic Rat Model
DR-BB Diabetic Rat Model
17 ± 3
54 ± 14 *
22 ± 2
26 ± 3
35 ± 3
67 ± 9 *
41 ± 7
152 ± 23 *
While whole-cell Ca2+ peaks declined by 30% with diabetes (Figure 1), separate analysis of the cytoplasmic and nuclear compartments demonstrated that most of the difference was attributable to the nuclear compartment. Figure 2B illustrates a significant decline in the amplitude of the vasopressin-induced Ca2+ peak in the nuclear compartment of both diabetic animal models compared to their controls as determined by the change of the fluorescence ratio (p < 0.01). The amplitude of the nuclear thapsigargin response was not different in VSMC from control or diabetic animals using either animal model (Figure 2C).
In order to rule out general changes in the nuclear envelope that could alter Ca2+ signaling, two nucleus-specific proteins were analyzed. Both p62 and NUP153 are core components of the nuclear pore complex, and levels and distribution of both proteins has been shown to be associated with specific disease states . Immunoblotting for p62 showed no difference in protein levels in samples from control or diabetic animals. In the STZ model of diabetes, the aortic VSMC p62 protein band density level was 67 ± 15 (arbitrary units) in control animals, and 70 ± 16 in diabetic tissue (no statistical difference). Similar results were found in the DR-BB aortic arteries. The values for p62 protein bands were 114 ± 6 in controls and 92 ± 15 in diabetes. In the femoral artery of the DR-BB animals, the levels were 62 ± 10 for controls and 77 ± 6 in diabetic rats. Like p62, levels of NUP153 also were not statistically different in the STZ or DR-BB rats in either the aortic or femoral VSMCs, suggesting that changes in nuclear Ca2+ transients were not likely associated with gross changes in nuclear transport.
Hyperglycemia attenuates Ca2+ responses in cultured VSMCs
When stimulated with vasopressin or thapsigargin, cells responded with an immediate increase in intracellular Ca2+ that was diminished by high glucose conditions. Figure 3B illustrates the altered responses to both vasopressin (time 0) and thapsigargin (TSG, arrow) from cells grown in medium and high glucose conditions. The different resting Ca2+ levels made it difficult to determine a change in vasopressin- induced peak responses. In order to compare the amplitude of the responses, the differences in baseline Ca2+ concentrations were normalized by dividing values by the resting Ca2+ fluorescence values (F/Fo) following the methods reported previously . The normalization clearly illustrates the attenuated peak response of the cells to either agonist in hyperglycemic conditions (Figure 3C).
Under medium and low glucose conditions, the timing of the Ca2+ transient was synchronous between the cytoplasmic and nuclear compartments of the A7r5 cells. Cells grown in medium and low glucose conditions (n = 74 and 97 cells, respectively) displayed 99% synchrony in the nuclear and cytoplasmic Ca2+ signals produced by vasopressin or thapsigargin. Asynchrony between the nuclear and cytoplasmic Ca2+ transients with stimulation was significantly increased in cells grown in high glucose, resulting in 13% of the total cells demonstrating asynchronous behavior (n = 138 cells).
Diabetes and Hyperglycemia Altered Levels of SERCA Proteins
Levels of Ca2+ Regulatory Proteins are Changed with Diabetes
STZ-Induced Diabetic Rat Model
DR-BB Diabetic Rat Model
165 ± 4
121 ± 12 *
120 ± 15
81 ± 9 *
108 ± 3
56 ± 2 *
69 ± 19
60 ± 14
161 ± 13
110 ± 15 *
78 ± 5
38 ± 15 *
IP 3 R type 1
40 ± 9
19 ± 8 *
213 ± 22
228 ± 28
135 ± 23
42 ± 6 *
IP 3 R type 2
37 ± 4
18 ± 3 *
38 ± 5
95 ± 8 *
11 ± 5
72 ± 59
Diabetes and Hyperglycemia Alter Distribution of SERCA Proteins
Diabetes and Hyperglycemia Altered Levels of Intracellular Ca2+ Channels
The channels responsible for releasing Ca2+ from the intracellular stores are the inositol trisphosphate receptor (IP3R) and the ryanodine receptor (RyR). There are three subtypes of IP3Rs, and each was examined in the aorta of the diabetic animal models and in cultured cells exposed to hyperglycemic conditions. Type 1 IP3Rs (IP3R-1) showed a significant decline in levels in the aortas from both models of diabetes with a 69% decline in the DR-BB diabetic animals and a 53% decline in the STZ rats (Figure 6B, Table 3). Type 2 IP3R (IP3R-2) were only tested in the genetically-prone DR-BB model of diabetes, showing a significant decline with diabetes. IP3R type 3 (IP3R-3) levels were not detected in amounts allowing immunoblot analysis of protein levels in either animal model.
A reduction in the levels of the IP3R prompted investigation of the other major SR Ca2+ release channel in smooth muscle cells, the RyR to determine whether its subcellular distribution changed, possibly in response to changes in the IP3R. We hypothesized that the RyR could be either down-regulated due to a decline in cellular Ca2+ signaling or upregulated as a compensatory mechanism for the decline in IP3R protein levels and cellular signaling. The RyR, increased dramatically with diabetes, regardless of the animal model (Table 3). In the STZ rats there was 2.5 times more RyR measured in the aorta when compared to non-diabetic controls. Interestingly, in the DR-BB rats there was an exquisite correlation between glucose levels and the amount of RyR. If the blood glucose was greater than 300 mg/dL on the day of sacrifice, then higher RyR levels were noted. However, if the diabetic rat had a lower glucose reading on that day, even if they had been hyperglycemic in the past, the changes in the RyR levels were minimal. This variability resulted in a lack of statistically significant differences found when comparing the diabetic to the control animals (Table 3).
In cultured VSMCs exposed to hyperglycemia, a decreased amount of protein for all three IP3R subtypes was observed under high glucose conditions (Figure 7). The levels of IP3R-1 decreased nearly 2.5 fold with high glucose exposure (Table 3). Although there was variability in the amount of protein normally present between the cytoplasm and nuclear compartments, in all cases high glucose treatment reduced the amount of IP3R-1 in each compartment. IP3R-2, detected mainly in nuclear extracts decreased 20% with high glucose exposure (Figure 7). IP3R-3 was detected in both the nucleus and cytoplasm in medium glucose conditions. However, in high glucose the levels decreased an average of 90% in the cytoplasm and decreased 30% in the nucleus (Figure 7).
Diabetes and Hyperglycemia Altered the Distribution of Intracellular Ca2+ Channels
RyR immunostaining was primarily cytoplasmic with nuclear exclusion as the most common pattern, although some cells showed a more generalized staining in control that included the nuclear region. While the distribution of RyR was similar to the IP3R pattern, the fluorescence intensity was affected by diabetes in a manner that was just opposite to the IP3R response. Consistent with the protein levels measured with immunoblotting, the VSMCs from diabetic rats demonstrated significantly higher levels of RyR immunostaining compared to the cells from control animals (not shown). This was true of both diabetic animal models and A7r5 cells grown in high glucose concentrations. Immunostaining of the RyR demonstrated primarily patchy cytoplasmic staining with strong perinuclear localization (Figure 10G). A predominant relocation to the nucleus was observed for the RyR when cells were grown in high glucose (Figure 10H).
VSMC dysfunction and subsequent disease is the main cause of mortality in type 1 diabetes, but the underlying mechanisms are largely unknown. In normal (medium) glucose conditions reported here, the distribution of the IP3R subtypes, RyR, and SERCA were similar to other studies using primary aortic SMCs , rabbit aortic SMCs , and cultured cell lines . Studies involving rat heart , islet cells and kidney  using diabetic animal models have demonstrated alterations in IP3R-1, SERCA2 and SERCA3 expression in a manner very consistent with our results from VSMCs.
The results of this study clearly demonstrate changes in the regulatory proteins associated with intracellular Ca2+ storage and release in aortic and femoral VSMCs. These changes lead to altered Ca2+ signaling in the cytoplasmic and nuclear compartments in response vasopressin. VSMCs from two different diabetic rat models showed a decline in the levels of IP3R and SERCA protein with diabetes. Changes in the distribution of the IP3R subtypes and SERCA subtypes were dependent on the rat model, but fully supported the immunoblot results of overall decreased amounts. To measure the relative role of hyperglycemia on the above mentioned changes, rat aortic cultured cells (A7r5) were exposed to various concentrations of glucose. Like the freshly dispersed cells from the diabetic animals, cultured cells exposed to high glucose had blunted Ca2+ responses to vasopressin and decreased levels of Ca2+ regulatory proteins. Thus, the changes noted in vSMCs from diabetic animals were likely due to exposure of the vSMCs to hyperglycemic conditions rather than adaptation of the cells to the complex disease of diabetes. This is the first study to report of both diminished levels and subcellular redistribution of key Ca2+ regulatory proteins in cultured and freshly dispersed VSMCs.
Previous studies have described a blunted Ca2+ response in VSMCs from diabetic animals [28–30]. Unique to this study was the identification of separate nuclear and cytoplasmic responses, and the presence of spontaneous nuclear Ca2+ oscillations. Such oscillations in A7r5 cells have been reported to be associated with intracellular Ca2+ stores and entry of Ca2+ from the extracellular milieu [31, 22]. Others have shown spontaneous Ca2+ sparks occurring around the nucleus of primary VSMCs . The effect of glucose on the spontaneous nuclear oscillations has not been previously published. In this study, the high magnitude spontaneous oscillations in resting cells bathed in high glucose were intracellular Ca2+ release events as all experiments were performed in zero extracellular Ca2+.
In order to thoroughly examine the effects of hyperglycemia on VSMC function, two different animal models of type 1 diabetes were utilized; the toxin-induced STZ diabetic rat and the immune/inflammation model of type 1 diabetes, the DR-BB rat. The differences noted between the two models were minor, but in general the diabetes induced changes were more robust in the DR-BB rats. It is possible that any small differences we noted between rat models were a function of the rat strain, the method of diabetic induction, or the administration of insulin to the DR-BB animals.
In VSMCs, much of the ability to remove Ca2+ from the cytoplasm is dependent on the SERCA proteins on the SR and nuclear envelope, estimated to be responsible for over 40% of the Ca2+ buffering in VSMCs [33, 34]. Importantly, by maintaining low intracellular Ca2+, SERCA inhibits migration of VSMCs into the intima of the vessel , a common hallmark of diabetes-induced vascular disease. In general, SERCA2 and SERCA3 protein levels were decreased and their distribution altered in the diabetic rats. Brefeldin A staining of the SR did not show a corresponding loss or reorganization of the SR with hyperglycemia, suggesting that these were pump-specific changes. In contrast to a previous report , we did not measure an increase in degradation in SERCA proteins with diabetes. In VSMCs from diabetic animals, SERCA2 shifted from a generalized SR distribution to a perinuclear location coupled with an overall decrease in the SERCA protein levels. SERCA2 is the primary Ca2+-ATPase of the SR in VSMCs and is thought to be most important in cytoplasmic Ca2+ buffering . Changes in the thapsigargin-induced Ca2+ transient suggest that the decrease in protein levels affected the ability of the cells to buffer Ca2+ via SERCA as has been shown in other labs .
The function of SERCA3 in VSMCs still remains elusive. Originally SERCA3 was reported to be absent from muscle cells. However, thorough examination of tissues with subtype-specific antibodies, revealed that at least one member of the SERCA3 family was equally expressed in all tissues tested . In human vascular endothelial cells, chronic stimulation with histamine caused an upregulation in the SERCA3 protein, which allowed quicker sequestration of Ca2+ from the cytoplasm following stimulation . Given such results in endothelial cells, it is reasonable to consider that a decrease in the SERCA3 levels could partially explain the delayed and blunted response to thapsigargin in the VSMC shown here. The importance of this little defined protein should not be overlooked, as the SERCA3 locus has been implicated in the genetic susceptibility in human type 2 diabetes .
Vascular reactivity to vasopressin in diabetes varies between vascular beds [42, 43]. For this reason, the protein levels and Ca2+ responses were tested in VSMCs from both the aorta and the femoral arteries. The diabetes-induced changes in protein levels and in the Ca2+ responses were the same in VSMCs from either location with the exception of SERCA2 levels, which were increased in the femoral artery, but decreased in the aortic VSMCs in the STZ rat. This increase in the femoral artery agrees with a study finding increased SERCA activity and levels in resistance arteries from diabetic dyslipidemic pigs . SERCA2 may be of more functional importance in the resistance arteries so these findings may serve as a cautionary note for researchers drawing conclusions from aortic tissue alone.
When analyzing the Ca2+ channel activity, the results presented here build on earlier work by Ma et al., illustrating a decline in IP3 responses in VSMCs from STZ treated rats . The Ma paper showed a decline in vessel contractility and in intracellular Ca2+ responses via IP3 receptors and Ca2+ influx across the plasma membrane. A decrease in IP3R-1 levels in diabetic arteriolar SMCs has been published previously . The current study focused the question on the level of specific Ca2+ regulatory proteins on the SR by conducting live cell experiments in zero extracellular Ca2+ conditions. Further, we showed that the findings were not dependent on the mode used to induce diabetes, using either a toxin-induced rat model or genetically-bred animals, as the results were generally consistent in the aorta and femoral arteries of the STZ and DR-BB animals. The results suggest that the decreased activity in the VSMCs associated with diabetes is due to shared changes in the SR Ca2+ release channels (IP3R) and SERCA resulting in diminished Ca2+ transients, especially in the nuclear compartment. In addition to selectively activating genes, nuclear Ca2+ may also play an important role in stabilizing mRNA in a variety of cell types . The functional impact on differential gene expression of decreased Ca2+ responses in VSMCs as a result of diabetes is a question that should be intensely pursued, given the findings of this study.
The similarity of the results from identical experiments conducted in freshly dispersed cells from diabetic and control rats, and cultured rat aortic cells grown in normal and high glucose are striking and underlie the importance of chronic exposure to glucose as a major inducer of changes in intracellular Ca2+ regulation. Previous studies have shown direct effects of glucose on cultured cells, but have typically worked with primary cultures [47, 48, 35]. In such cases 20-25 mM Ca2+ in the extracellular media was sufficient to elicit a response similar to that seen in cells from diabetic animals. Due to the fact that we utilized a cultured cell line in which the normal growth media contained 25 mM glucose (referred to as medium in this study), we had to increase the glucose concentration dramatically to evoke a diabetes-like response. While the sensitivity to glucose was different in the culture cells, the other characteristics of the glucose-induced change in freshly dispersed and cultured cells were exceedingly similar.
The importance of separating the nuclear Ca2+ response from cytoplasmic may not be immediately clear. We are not the first to report on selective Ca2+ signals in the nuclear that were unique from the cytoplasm as Bkaily et al demonstrated in neurons [49, 50]. Nuclear and cytosolic Ca2+ have been reported to be regulated independently in several cell types [51, 52]. Zones of Ca2+ signaling around and within the nucleus of smooth muscle cells have led some to suggest that clusters of lysosomes with high densities of RyR form in the perinuclear region forming physical junctions with the SR to comprise a trigger zone of Ca2+. The result of the depressed nuclear Ca2+ signal with high glucose is unknown, but it is likely that VSMCs have nuclear-specific Ca2+ transcription regulated pathways just as neurons have been shown to possess [54, 55].
While diabetes is a complex disease that includes hyperglycemia, hypoinsulinemia or hyperinsulinemia and numerous adaptations in metabolic proteins as well as changes in regulatory factors, it appears that high glucose is predominantly responsible for the decreased IP3-induced Ca2+ transients noted previously in VSMCs from diabetic animals. This is likely due to the altered distribution and/or levels of Ca2+ regulatory proteins including the IP3R, RyR, and SERCA. Determining how diabetes changes protein distribution and amounts is paramount, as these changes clearly have downstream effects within the cells that may be linked to cell proliferation and migration.
Gratitude is offered to Dr. Doug Burns for his assistance in confocal microscopy. Funding for the project was provided by NIH (R01-GM55290) to LSB.
- Preis S, Hwang S, Coady S, Pencina M, D'Agostino RS, Savage P, Levy D, Fox C: Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009, 119: 1728-1735. 10.1161/CIRCULATIONAHA.108.829176.PubMed CentralView ArticlePubMedGoogle Scholar
- Soedamah-Muthu S, Stehouwer C: Cardiovascular disease morbidity and mortality in patients with type 1 diabetes mellitus: management strategies. Treat Endocrinol. 2005, 4: 75-86. 10.2165/00024677-200504020-00002.View ArticlePubMedGoogle Scholar
- Aronson D: Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol. 2008, 45: 1-16. full_text.View ArticlePubMedGoogle Scholar
- Laing S, Swerdlow A, Slater S, Burden A, Morris A, Waugh N, Gatling W, Bingley P, Patterson C: Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003, 46: 760-765. 10.1007/s00125-003-1116-6.View ArticlePubMedGoogle Scholar
- Luscher T, Creager M, Beckman J, Cosentino F: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Circulation. 2003, 108: 1655-1661. 10.1161/01.CIR.0000089189.70578.E2.View ArticlePubMedGoogle Scholar
- Aksnes T, Kjeldsen S, Rostrup M, Omvik P, Hua T, Julius S: Impact of new onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension. 2007, 50 (3): 467-473. 10.1161/HYPERTENSIONAHA.106.085654.View ArticlePubMedGoogle Scholar
- Soedamah-Muthu S, Chaturvedi N, Witte D, Stevens L, Porta M, Fuller J, Group EPCS: Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care. 2008, 31: 1360-1366. 10.2337/dc08-0107.PubMed CentralView ArticlePubMedGoogle Scholar
- Putaala J, Curtze S, Hiltunen S, Tolppanen H, Kaste M, Tatlisumak T: Causes of death and predictors of 5-year mortality in young adults after first-ever ischemic stroke: the Helsinki Young Stroke Registry. Stroke. 2009, 40: 2698-2703. 10.1161/STROKEAHA.109.554998.View ArticlePubMedGoogle Scholar
- Maser R, Wolfson SJ, Ellis D, Stein E, Drash A, Becker D, Dorman J, Orchard T: Cardiovascular disease and arterial calcification in insulin-dependent diabetes mellitus: interrelations and risk factor profiles. Pittsburgh Epidemiology of Diabetes Complications Study-V. Arterioscler Thromb. 1991, 11: 958-965. [http://atvb.ahajournals.org/cgi/reprint/11/4/958]View ArticlePubMedGoogle Scholar
- Karastergiou K, Kaski J: Medical management of the diabetic patient with coronary artery disease. Curr Pharm Des. 2008, 14: 2527-2536. 10.2174/138161208786071272.View ArticlePubMedGoogle Scholar
- Nacci C, Tarquinio M, De Benedictis L, Mauro A, Zigrino A, Carratù M, Quon M, Montagnani M: Endothelial dysfunction in mice with streptozotocin-induced type 1 diabetes is opposed by compensatory overexpression of cyclooxygenase-2 in the vasculature. Endocrinology. 2009, 150: 849-861. 10.1210/en.2008-1069.PubMed CentralView ArticlePubMedGoogle Scholar
- Bjarnegård N, Arnqvist H, Lindström T, Jonasson L, Jönsson A, Länne T: Long term hyperglycaemia impairs vascular smooth muscle cell function in women with type 1 diabetes mellitus. Diab Vasc Dis Res. 2009, 6: 25-31. 10.3132/dvdr.2009.005.View ArticlePubMedGoogle Scholar
- Dunn K, Nelsom M: Calcium and diabetic vascular dysfunction. Focus on "Elevated Ca2+ sparklet activity during acute hyperglycemia and diabetes in cerebral arterial smooth muscle. Am J Physiol Cell Physiol. 2010, 298: C203-C205.View ArticlePubMedGoogle Scholar
- Madi H, Riches K, Warburton P, O'Regan D, Turner N, Porter K: Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients. Am J Physiol Cell Physiol. 2009, 297: C1307-1317. 10.1152/ajpcell.00608.2008.View ArticlePubMedGoogle Scholar
- Orasanu G, Plutzky J: The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol. 2009, 53: S35-42. 10.1016/j.jacc.2008.09.055.PubMed CentralView ArticlePubMedGoogle Scholar
- Faries PL, Rohan DI, Takahara H, Wyers MC, Contreras MA, Quist WC, King GL, Logerfo FW: Human vascular smooth muscle cells of diabetic origin exhibit increased proliferation, adhesion, and migration. J Vasc Surg. 2001, 33: 601-607. 10.1067/mva.2001.111806.View ArticlePubMedGoogle Scholar
- Vranes D, Cooper ME, Dilley RJ: Cellular mechanisms of diabetic vascular hypertrophy. Microvasc Res. 1999, 57: 8-18. 10.1006/mvre.1998.2107.View ArticlePubMedGoogle Scholar
- Haddock R, Hill C: Differential activation of ion channels by inositol 1,4,5-trisphosphate (IP3)- and ryanodine-sensitive calcium stores in rat basilar artery vasomotion. J Physiol. 2002, 545: 615-627. 10.1113/jphysiol.2002.027904.PubMed CentralView ArticlePubMedGoogle Scholar
- Descorbeth M, Anand-Srivastava M: High glucose increases the expression of Gq/11alpha and PLC-beta proteins and associated signaling in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2008, 295: H2135-2142. 10.1152/ajpheart.00704.2008.View ArticlePubMedGoogle Scholar
- Sharma K, Deelman L, Madesh M, Kurz B, Ciccone E, Siva S, Hu T, Zhu Y, Wang L, Henning R: Involvement of transforming growth factor-beta in regulation of calcium transients in diabetic vascular smooth muscle cells. Am J Physiol Renal Physiol. 2003, 285: F1258-1270.View ArticlePubMedGoogle Scholar
- Kinoshita Y, Ito H, Hirano A, Fujita K, Wate R, Nakamura M, Kaneko S, Nakano S, Kusaka H: Nuclear contour irregularity and abnormal transporter protein distribution in anterior horn cells in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2009, 68: 1184-1192. 10.1097/NEN.0b013e3181bc3bec.View ArticlePubMedGoogle Scholar
- Fedoryak O, Searls Y, Smirnova I, Burns D, Stehno-Bittel L: Spontaneous Ca2+ oscillations in subcellular compartments of vascular smooth muscle cells rely on different Ca2+ pools. Cell Res. 2004, 14: 379-388. 10.1038/sj.cr.7290238.View ArticlePubMedGoogle Scholar
- Tasker PN, Taylor CW, Nixon GF: Expression and distribution of InsP(3) receptor subtypes in proliferating vascular smooth muscle cells. Biochem Biophys Res Commun. 2000, 273: 907-912. 10.1006/bbrc.2000.3036.View ArticlePubMedGoogle Scholar
- Abrenica B, Pierce GN, Gilchrist JS: Nucleoplasmic calcium regulation in rabbit aortic vascular smooth muscle cells. Can J Physiol Pharmacol. 2003, 81: 301-310. 10.1139/y03-005.View ArticlePubMedGoogle Scholar
- Vermassen E, Van Acker K, Annaert WG, Himpens B, Callewaert G, Missiaen L, De Smedt H, Parys JB: Microtubule-dependent redistribution of the type-1 inositol 1,4,5-trisphosphate receptor in A7r5 smooth muscle cells. J Cell Sci. 2003, 116: 1269-1277. 10.1242/jcs.00354.View ArticlePubMedGoogle Scholar
- Kim HW, Ch YS, Lee HR, Park SY, Kim YH: Diabetic alterations in cardiac sarcoplasmic reticulum Ca2+-ATPase and phospholamban protein expression. Life Sci. 2001, 70: 367-379. 10.1016/S0024-3205(01)01483-7.View ArticlePubMedGoogle Scholar
- Varadi A, Lebel L, Hashim Y, Mehta Z, Ashcroft SJ, Turner R: Sequence variants of the sarco(endo)plasmic reticulum Ca(2+)-transport ATPase 3 gene (SERCA3) in Caucasian type II diabetic patients (UK Prospective Diabetes Study 48). Diabetologia. 1999, 42: 1240-1243. 10.1007/s001250051298.View ArticlePubMedGoogle Scholar
- Ma L, Zhu B, Chen X, Liu J, Guan Y, Ren J: Abnormalities of sarcoplasmic reticulum Ca2+ mobilization in aortic smooth muscle cells from streptozotocin-induced diabetic rats. Clin Exp Pharmacol Physiol. 2008, 35: 568-573. 10.1111/j.1440-1681.2007.04832.x.View ArticlePubMedGoogle Scholar
- Sakai Y, Kwan CY: Calcium regulation and contractile dysfunction of smooth muscle. Biol Signals. 1993, 2: 305-312. 10.1159/000109511.View ArticlePubMedGoogle Scholar
- Wang R, Wu Y, Tang G, Wu L, Hanna ST: Altered L-type Ca(2+) channel currents in vascular smooth muscle cells from experimental diabetic rats. Am J Physiol Heart Circ Physiol. 2000, 278: H714-722.PubMedGoogle Scholar
- Wu SN, Yu HS, Seyama Y: Analytical studies of spontaneous and vasopressin-induced calcium oscillations in cultured vascular smooth muscle cells. J Biochem. 1996, 119 (1): 42-48.View ArticlePubMedGoogle Scholar
- Pucovský V, Bolton T: Localisation, function and composition of primary Ca(2+) spark discharge region in isolated smooth muscle cells from guinea-pig mesenteric arteries. Cell Calcium. 2006, 39: 113-129. 10.1016/j.ceca.2005.10.002.View ArticlePubMedGoogle Scholar
- Clapham DE: Calcium signaling. Cell. 1995, 80: 259-268. 10.1016/0092-8674(95)90408-5.View ArticlePubMedGoogle Scholar
- van Breemen C, Saida K: Cellular mechanisms regulating [Ca2+i] smooth muscle. Annu Rev Physiol. 1989, 51: 315-329. 10.1146/annurev.physiol.51.1.315.View ArticlePubMedGoogle Scholar
- Tong X, Ying J, Pimentel D, Trucillo M, Adachi T, Cohen R: High glucose oxidizes SERCA cysteine-674 and prevents inhibition by nitric oxide of smooth muscle cell migration. J Mol Cell Cardiol. 2008, 44: 361-369. 10.1016/j.yjmcc.2007.10.022.PubMed CentralView ArticlePubMedGoogle Scholar
- Ying J, Sharov V, Xu S, Jiang B, Gerrity R, Schöneich C, Cohen R: Cysteine-674 oxidation and degradation of sarcoplasmic reticulum Ca(2+) ATPase in diabetic pig aorta. Free Radic Biol Med. 2008, 45: 756-762. 10.1016/j.freeradbiomed.2008.05.029.PubMed CentralView ArticlePubMedGoogle Scholar
- Wu KD, Bungard D, Lytton J: Regulation of SERCA Ca2+ pump expression by cytoplasmic Ca2+ in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2001, 280: C843-851.PubMedGoogle Scholar
- David K, Scott R, Nixon G: Advanced glycation endproducts induce a proliferative response in vascular smooth muscle cells via altered calcium signaling. Biochem Pharmacol. 2008, 76: 1110-1120. 10.1016/j.bcp.2008.08.011.View ArticlePubMedGoogle Scholar
- Martin V, Bredoux R, Corvazier E, Van Gorp R, Kovacs T, Gelebart P, Enouf J: Three novel sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 3 isoforms. Expression, regulation, and function of the membranes of the SERCA3 family. J Biol Chem. 2002, 277: 24442-24452. 10.1074/jbc.M202011200.View ArticlePubMedGoogle Scholar
- Hadri L, Pavoine C, Lipskaia L, Yacoubi S, Lompré A: Transcription of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase type 3 gene, ATP2A3, is regulated by the calcineurin/NFAT pathway in endothelial cells. Biochem J. 2006, 394: 27-33. 10.1042/BJ20051387.PubMed CentralView ArticlePubMedGoogle Scholar
- Varadi A, Lebel L, Hashim Y, Mehta Z, Ashcroft S, Turner R: Sequence variants of the sarco(endo)plasmic reticulum Ca(2+)-transport ATPase 3 gene (SERCA3) in Caucasian type II diabetic patients (UK Prospective Diabetes Study 48). Diabetologia. 1999, 42: 1240-1243. 10.1007/s001250051298.View ArticlePubMedGoogle Scholar
- Jaffer U, Aslam M, Standfield N: Impaired hyperaemic and rhythmic vasomotor response in type 1 diabetes mellitus patients: a predictor of early peripheral vascular disease. Eur J Vasc Endovasc Surg. 2008, 35: 603-606. 10.1016/j.ejvs.2007.12.006.View ArticlePubMedGoogle Scholar
- Gurney A, Howarth F: Effects of streptozotocin-induced diabetes on the pharmacology of rat conduit and resistance intrapulmonary arteries. Cardiovasc Diabetol. 2009, doi: 10.1186/1475-2840-8-4Google Scholar
- Hill B, Price E, Dixon J, Sturek M: Increased calcium buffering in coronary smooth muscle cells from diabetic dyslipidemic pigs. Atherosclerosis. 2003, 167: 15-23. 10.1016/S0021-9150(02)00381-7.View ArticlePubMedGoogle Scholar
- McGowan TA, Sharma K: Regulation of inositol 1,4,5-trisphosphate receptors by transforming growth factor-beta: implications for vascular dysfunction in diabetes. Kidney Int Suppl. 2000, 77: S99-103. 10.1046/j.1523-1755.2000.07716.x.View ArticlePubMedGoogle Scholar
- Misquitta C, Chen T, Grover A: Control of protein expression through mRNA stability in calcium signalling. Cell Calcium. 2006, 40: 329-346. 10.1016/j.ceca.2006.04.004.View ArticlePubMedGoogle Scholar
- Nilsson J, Nilsson L, Chen Y, Molkentin J, Erlinge D, Gomez M: High glucose activates nuclear factor of activated T cells in native vascular smooth muscle. Arterioscler Thromb Vasc Biol. 2006, 26: 794-800. 10.1161/01.ATV.0000209513.00765.13.View ArticlePubMedGoogle Scholar
- Schaeffer G, Levak-Frank S, Spitaler M, Fleischhacker E, Esenabhalu V, Wagner A, Hecker M, Graier WF: Intercellular signalling within vascular cells under high D-glucose involves free radical-triggered tyrosine kinase activation. Diabetologia. 2003, 46: 773-783. 10.1007/s00125-003-1091-y.View ArticlePubMedGoogle Scholar
- Bkaily G, Choufani S, Avedanianm L, Ahmarani L, Nader M, Jacques D, D'Orléans-Juste P, Al Khoury J: Nonpeptidic antagonists of ETA and ETB receptors reverse the ET-1-induced sustained increase of cytosolic and nuclear calcium in human aortic vascular smooth muscle cells. Can J Physiol Pharmacol. 2008, 86: 546-556. 10.1139/Y08-048.View ArticlePubMedGoogle Scholar
- Bkaily G, Nader M, Avedanian L, Choufani S, Jacques D, D'Orléans-Juste P, Gobeil F, Chemtob S, Al-Khoury J: G-protein-coupled receptors, channels, and Na+-H+ exchanger in nuclear membranes of heart, hepatic, vascular endothelial, and smooth muscle cells. Can J Physiol Pharmacol. 2006, 84: 431-441. 10.1139/Y06-002.View ArticlePubMedGoogle Scholar
- Leite MF, Thrower EC, Echevarria W, Koulen P, Hirata K, Bennett AM, Ehrlich BE, Nathanson MH: Nuclear and cytosolic calcium are regulated independently. Proc Natl Acad Sci USA. 2003, 100: 2975-2980. 10.1073/pnas.0536590100.PubMed CentralView ArticlePubMedGoogle Scholar
- Stehno-Bittel L, Luckhoff A, Clapham DE: Calcium release from the nucleus by InsP3 receptor channels. Neuron. 1995, 14: 163-167. 10.1016/0896-6273(95)90250-3.View ArticlePubMedGoogle Scholar
- Kinnear N, Wyatt C, Clark J, Calcraft P, Fleischer S, Jeyakumar L, Nixon G, Evans A: Lysosomes co-localize with ryanodine receptor subtype 3 to form a trigger zone for calcium signalling by NAADP in rat pulmonary arterial smooth muscle. Cell Calcium. 2008, 44: 190-201. 10.1016/j.ceca.2007.11.003.PubMed CentralView ArticlePubMedGoogle Scholar
- Papadia S, Stevenson P, Hardingham N, Bading H, Hardingham G: Nuclear Ca2+ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection. J Neurosci. 2005, 25 (17): 4279-4287. 10.1523/JNEUROSCI.5019-04.2005.View ArticlePubMedGoogle Scholar
- Lau D, Bading H: Synaptic activity-mediated suppression of p53 and induction of nuclear calcium-regulated neuroprotective genes promote survival through inhibition of mitochondrial permeability transition. J Neurosci. 2009, 29: 4420-4429. 10.1523/JNEUROSCI.0802-09.2009.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.